The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels

Figure 3

Changes in cfDNA levels. cfDNA levels were measured at baseline and following 8-week treatment with either placebo (a) or rosiglitazone (b). There were no differences between levels at baseline or follow-up in either group ( for placebo and for rosiglitazone). However, the proportion of patients who had a decrease in their cfDNA levels over the course of the trial was significantly higher in the rosiglitazone-treated group (), shown in (c) as the filled area.

(a)

(b)

(c)